Detalhe da pesquisa
1.
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
Lancet Oncol
; 19(4): 474-485, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29482983
2.
Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.
Oncologist
; 20(8): 880-9, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26099741
3.
Ovarian Reserve after Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis.
J Pers Med
; 11(8)2021 Jul 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34442350
4.
Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study.
ESMO Open
; 5(4)2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32817059
5.
Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial.
Cancer Lett
; 400: 276-281, 2017 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28131905
6.
MALDI-MS-NIST library approach for colorectal cancer diagnosis.
Rapid Commun Mass Spectrom
; 23(17): 2839-45, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19653206